These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31686855)

  • 1. Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin.
    Zang S; Zhao S; Gao X; Li Y; Zhong C; Gao J
    Onco Targets Ther; 2019; 12():7551-7560. PubMed ID: 31686855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
    Lu T; Lu W; Jia C; Lou S; Zhang Y
    Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway.
    Lin Z; Pan J; Chen L; Wang X; Chen Y
    Onco Targets Ther; 2020; 13():8149-8160. PubMed ID: 32884297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism.
    Liu Y; He C; Huang X
    Oncotarget; 2017 Sep; 8(43):75206-75216. PubMed ID: 29088858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN.
    Liang N; Zhou X; Zhao M; Zhao D; Zhu Z; Li S; Yang H
    Acta Biochim Biophys Sin (Shanghai); 2015 Jul; 47(7):530-8. PubMed ID: 26068649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
    Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
    Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
    Fan D; Yang Y; Zhang W
    BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein.
    Ma W; Cui Y; Liu M; Tan Z; Jiang Y
    Aging (Albany NY); 2019 May; 11(9):2670-2680. PubMed ID: 31056533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
    Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
    Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
    Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis.
    Xiao H; Liu Y; Liang P; Wang B; Tan H; Zhang Y; Gao X; Gao J
    Cell Biosci; 2018; 8():23. PubMed ID: 29588850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
    Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
    Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).
    Wang Y; Wu Y; Xie S
    Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.